Date: 17/02/2011
Phillip Securities Research in a Feb 14 research report says: "2Q11 revenue was down 9.6% y-o-y to HK$153.6 million while net profit came in at HK$28.7 million (-2.7% y-o-y) as suppliers are unwilling to procure more drugs due to the uncertainties surrounding the Chinese government's healthcare policies.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
